Table 6.
Procedural characteristics in patients with and without PAD by anticoagulant type
| No PAD 682 (85%) | PAD 119 (15%) | |||
|---|---|---|---|---|
| Bivalirudin 344 (50.4%) | UFH 338 (49.6%) | Bivalirudin 60 (50.4%) | UFH 59 (49.6%) | |
| Anesthesia type | ||||
| General | 136 (40.1) | 134 (40.1) | 17 (29.3) | 22 (37.9) |
| Local | 189 (55.8) | 183 (54.8) | 39 (67.2) | 33 (56.9) |
| Other | 14 (4.1) | 17 (5.1) | 2 (3.5) | 3 (5.2) |
| Procedural success | 309 (91.2) | 311 (93.1) | 50 (87.7) | 55 (94.8) |
| Balloon‐Expanding valve | 212 (61.6) | 215 (63.6) | 39 (65.0) | 34 (57.6) |
| Duration of procedure (min) median (IQR) | 24 (16–35) | 25 (17–34) | 28 (17–38) | 25 (18–35) |
| Sheath size of valve system | ||||
| <18 | 107 (31.9) | 108 (32.6) | 21 (36.2) | 19 (23.8) |
| 18 | 187 (55.8) | 176 (53.2) | 29 (50.0) | 31 (53.5) |
| >18 | 41 (12.2) | 47 (14.2) | 8 (13.8) | 8 (13.8) |
| Valve type | ||||
| Balloon expandable | 212 (61.3) | 215 (63.6) | 39 (65.0) | 34 (57.6) |
| Self‐expanding | 99 (28.8) | 99 (29.3) | 16 (26.7) | 17 (28.8) |
| Other valve | 33 (5.6) | 24 (7.1) | 5 (8.3) | 8 (13.6) |
| Valve size | ||||
| ES 23 mm | 65 (19.3) | 60 (18.1) | 15 (26.3) | 10 (17.2) |
| ES 26 mm | 91 (27.0) | 87 (26.3) | 12 (21.1) | 10 (17.2) |
| ES 29 mm | 35 (10.4) | 44 (13.3) | 6 (10.5) | 10 (17.2) |
| MCV 26 mm | 30 (8.9) | 31 (9.4) | 3 (5.3) | 5 (8.6) |
| MCV 29 mm | 39 (11.6) | 37 (11.2) | 6 (10.5) | 6 (10.3) |
| MCV 31 mm | 23 (6.8) | 18 (5.4) | 6 (10.5) | 6 (10.3) |
| Other | 54 (16.0) | 54 (16.3) | 9 (15.8) | 11 (19.0) |
| Valvuloplasty performed | 275 (80.4) | 269 (80.1) | 50 (84.8) | 43 (74.1) |
| Additional TAVR device used | 16 (4.8) | 12 (3.6) | 0 (0.0) | 0 (0.0) |
| Embolic protection device used | 5 (1.5) | 2 (0.6) | 2 (3.5) | 1 (1.7) |
| Successful deployment of access site closure | 309 (91.2) | 311 (93.1) | 50 (87.7) | 55 (94.8) |
| Post‐dilation | 97 (28.4) | 73 (21.7) | 15 (24.4) | 14 (24.1) |
| Temporary pacemaker | 323 (96.7) | 326 (98.2) | 54 (93.1) | 54 (94.7) |
| Prior loading with clopidogrel | 131 (38.2) | 123 (36.5) | 21 (35.6) | 18 (30.5) |
| Post‐procedure anti‐thrombotic therapy in patients with and without PAD by anticoagulant type | ||||
|---|---|---|---|---|
| No PAD 682 (85%) | PAD 119 (15%) | |||
| Bivalirudin 344 (50.4%) | UFH 338 (49.6%) | Bivalirudin 60 (50.4%) | UFH 59 (49.6%) | |
| Aspirin | 293 (85.7) | 294 (12.8) | 50 (84.8) | 54 (91.5) |
| P2Y12 inhibitor | 248 (72.5) | 249 (73.9) | 51 (86.4) | 46 (78.0) |
| ASA and P2Y12 inhibitor | 219 (63.7) | 220 (65.1) | 45 (75.0) | 42 (71.2) |
| Oral anticoagulant | ||||
| Coumadin | 62 (18.0) | 59 (17.5) | 12 (20.0) | 8 (13.6) |
| Dabigatran | 2 (0.6) | 7 (2.1) | 2 (3.3) | 0 (0.0) |
| Rivaroxaban | 8 (2.3) | 12 (3.6) | 3 (5.0) | 1 (1.7) |